Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] - BSA and Azide free (ab256581)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [MJFR-19-7-8] to LRRK2 (phospho S1292) - BSA and Azide free
  • Suitable for: WB
  • Reacts with: Human

Overview

  • Product name

    Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] - BSA and Azide free
    See all LRRK2 primary antibodies

  • Description

    Rabbit monoclonal [MJFR-19-7-8] to LRRK2 (phospho S1292) - BSA and Azide free

  • Host species

    Rabbit

  • Tested Applications & Species

    Application Species
    WB
    Human
    See all applications and species data

  • Immunogen

    Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.

  • Positive control

    • WB: GFP-LRRK2 mutant G2019S transfected HEK293 lysate subjected to immunoprecipitation with GFP trap agarose.

  • General notes

    ab206035 is a carrier-free version of ab203181. This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.

    Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.

    Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with

    ab256581 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.

    Maxpar® is a trademark of Fluidigm Canada Inc.

     

    This antibody was developed with support from The Michael J. Fox Foundation.

     

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

Properties

Images

  • Western blot - Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] - BSA and Azide free (ab256581)
    Western blot - Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] - BSA and Azide free (ab256581)
    Lane 1 : Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] (ab203181) at 1 µg
    Lanes 2-6 : Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] (ab203181) at 1 µg/ml

    Lane 1 : LRRK2 mutant G2019S/S1292A transfected HEK293 lysate
    Lane 2 : LRRK2 mutant G2019S transfected HEK293 inhibitor treated lysate
    Lane 3 : LRRK2 mutant G2019S transfected HEK293 lysate
    Lane 4 : LRRK2 mutant S1292A transfected HEK293 lysate
    Lane 5 : LRRK2 wt transfected HEK293 inhibitor treated lysate
    Lane 6 : LRRK2 wt transfected HEK293 lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : Goat anti-rabbit HRP at 1/2500 dilution

    Predicted band size: 286 kDa



    This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab203181).

    Blocking/Dilution buffer: 5% NFDM/TBST.

    The image is provided by Dr. Paul Davies, University of Dundee, Dundee Scotland, UK.

    G2019S mutation results in an increased LRRK2 auto-phosphorylation including S1292 (lane 3).

  • Western blot - Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] - BSA and Azide free (ab256581)
    Western blot - Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] - BSA and Azide free (ab256581)
    All lanes : Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] (ab203181) at 1 µg/ml

    Lane 1 : GFP-LRRK2 wt transfected HEK293 lysate subjected to immunoprecipitation with GFP trap agarose
    Lane 2 : GFP-LRRK2 mutant D2017A transfected HEK293 lysate subjected to immunoprecipitation with GFP trap agarose
    Lane 3 : GFP-LRRK2 mutant S1292A/G2019S transfected HEK293 lysate subjected to immunoprecipitation with GFP trap agarose
    Lane 4 : GFP-LRRK2 mutant G2019S transfected HEK293 lysate subjected to immunoprecipitation with GFP trap agarose

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : Goat anti-rabbit (IRDye 800) at 1/10000 dilution

    Predicted band size: 286 kDa



    This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab203181).

    Blocking/Dilution buffer: 5% BSA/TBST.

    The image is provided by Dr. Jeremy Nicols, Parkinson’s Institute, Sunnyvale, CA, USA.

    G2019S mutation results in an increased LRRK2 auto-phosphorylation including S1292 (lane 4).

    Observed band size: 286 + 27 (GFP) = 313 kDa.

  • Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] - BSA and Azide free (ab256581)
    Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] - BSA and Azide free (ab256581)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Alternative products to Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] - BSA and Azide free (ab256581)

© 2021 Astana Biomed Group LLP. All rights reserved.